It targets several receptors implicated in tumor growth and angiogenesis, including KIT, VEGFR2 (KDR), VEGFR3 (FLT4), and FLT3, making it a candidate for treating GISTs, particularly in patients who have developed resistance to standard therapies like imatinib [97]. Here, KDR is linked to neoplasm.